Compare Stocks → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LUMONASDAQ:ONTXNASDAQ:VINCNASDAQ:YMTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUMOLumos Pharma$3.02+7.5%$2.83$2.41▼$4.55$24.51M0.6523,214 shs270,583 shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsVINCVincerx Pharma$0.89+7.2%$4.01$0.61▼$9.37$19.04M1.11.23 million shs288,651 shsYMTXYumanity Therapeutics$0.55-1.8%$0.85$0.95▼$13.23$5.98M0.32473,083 shs157,067 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUMOLumos Pharma+5.23%+7.09%+5.59%+0.33%-5.63%ONTXOnconova Therapeutics0.00%0.00%-0.47%+38.81%-6.98%VINCVincerx Pharma+7.52%-4.39%-84.80%-25.28%-42.63%YMTXYumanity Therapeutics-2.37%-11.13%+8.79%-78.64%-86.43%#1 election stock (Ad)I’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLUMOLumos Pharma2.2184 of 5 stars3.51.00.00.00.02.51.3ONTXOnconova Therapeutics0.7921 of 5 stars3.53.00.00.00.00.00.0VINCVincerx Pharma1.8451 of 5 stars3.52.00.00.02.22.50.0YMTXYumanity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUMOLumos Pharma3.00Buy$18.00496.03% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideVINCVincerx Pharma3.00Buy$5.00462.30% UpsideYMTXYumanity TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest YMTX, LUMO, ONTX, and VINC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/1/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUMOLumos Pharma$2.05M11.95N/AN/A$3.45 per share0.88ONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00VINCVincerx PharmaN/AN/AN/AN/A$0.52 per shareN/AYMTXYumanity Therapeutics$4.84M1.24N/AN/A$2.28 per share0.24Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)VINCVincerx Pharma-$40.16M-$1.89N/AN/AN/AN/A-187.73%-126.26%5/9/2024 (Estimated)YMTXYumanity Therapeutics-$39.50M-$3.00N/A∞N/A-660.61%-263.34%-107.08%N/ALatest YMTX, LUMO, ONTX, and VINC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023VINCVincerx PharmaN/A-$0.23-$0.23-$0.23N/AN/A3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLUMOLumos PharmaN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/AYMTXYumanity TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUMOLumos PharmaN/A5.695.69ONTXOnconova TherapeuticsN/A2.792.79VINCVincerx PharmaN/A2.632.63YMTXYumanity TherapeuticsN/A2.212.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUMOLumos Pharma33.99%ONTXOnconova Therapeutics7.95%VINCVincerx Pharma44.02%YMTXYumanity Therapeutics25.10%Insider OwnershipCompanyInsider OwnershipLUMOLumos Pharma25.40%ONTXOnconova Therapeutics3.30%VINCVincerx Pharma22.90%YMTXYumanity Therapeutics12.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableVINCVincerx Pharma4221.41 million16.51 millionNot OptionableYMTXYumanity Therapeutics4010.86 million9.50 millionNot OptionableYMTX, LUMO, ONTX, and VINC HeadlinesSourceHeadlineYumanity Therapeutics (NASDAQ:YMTX) Stock Price Up 20.5%americanbankingnews.com - April 24 at 2:18 AMJSPR Jasper Therapeutics, Inc.seekingalpha.com - March 20 at 7:11 PMCara Therapeutics Inc CARAmorningstar.com - November 3 at 7:42 AMYumanity Therapeutics Inc.thestreet.com - October 6 at 6:24 PMFormer Onyx CEO Returns to Biotech to Launch Boston Start Upthestreet.com - July 5 at 1:02 AMKineta raises $6M through registered direct offeringbizjournals.com - May 1 at 1:51 AMColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reportsfinance.yahoo.com - February 22 at 10:00 AMYumanity Therapeutics's Return On Capital Employed Insightsmsn.com - December 26 at 1:21 PMKineta finalizes reverse merger with Yumanity, secures additional fundingbizjournals.com - December 20 at 6:58 PMYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...bakersfield.com - December 5 at 6:26 PMYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kinetafinance.yahoo.com - December 5 at 6:26 PMWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?investorplace.com - December 5 at 3:03 PMYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developmentsfinanznachrichten.de - November 14 at 11:42 AMYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developmentsfinance.yahoo.com - November 14 at 11:42 AMYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.finance.yahoo.com - November 10 at 4:45 PMYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kinetafinance.yahoo.com - August 29 at 10:16 AMYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developmentsfinance.yahoo.com - August 4 at 6:52 PMGlioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless Opportunitiesmedgadget.com - July 14 at 1:51 AMYUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…lawyer-monthly.com - July 5 at 10:55 PMInside Kineta's plans after unveiling reverse merger dealfinance.yahoo.com - June 8 at 9:39 PMSeattle biotech Kineta to go public in merger deal with Yumanity Therapeuticsbizjournals.com - June 7 at 11:47 PMShort Volatility Alert: Yumanity Therapeutics, Inc.msn.com - June 7 at 6:47 PMYumanity leaps as it reveals Janssen asset purchase and merger deal with Kinetathepharmaletter.com - June 6 at 5:23 PMYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXmarketwatch.com - June 6 at 12:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Vincerx PharmaNASDAQ:VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Yumanity TherapeuticsNASDAQ:YMTXYumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.